Nifty
Sensex
:
:
10890.30
36321.29
3.50 (0.03%)
2.96 (0.01%)

Pharmaceuticals & Drugs

Rating :
57/99

BSE: 500257 | NSE: LUPIN

863.20
13.50 (1.59%)
16-Jan-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  850.40
  •  865.50
  •  845.10
  •  849.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1681645
  •  14515.96
  •  986.10
  •  723.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 39,022.23
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,757.00
  • 0.58%
  • 2.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.98%
  • 1.13%
  • 11.34%
  • FII
  • DII
  • Others
  • 0.39%
  • 10.95%
  • 29.21%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.12
  • 6.97
  • 3.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.59
  • 0.95
  • -3.11

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.87
  • -33.01
  • -52.11

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.61
  • 26.48
  • 24.72

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.80
  • 5.75
  • 4.28

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.30
  • 16.61
  • 15.11

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
3,951.06
3,951.96
-0.02%
3,855.93
3,869.58
-0.35%
4,033.83
4,253.30
-5.16%
3,975.62
4,482.87
-11.32%
Expenses
3,401.42
3,098.91
9.76%
3,328.96
3,101.21
7.34%
3,325.08
3,471.93
-4.23%
3,287.28
3,264.24
0.71%
EBITDA
549.64
853.05
-35.57%
526.97
768.37
-31.42%
708.75
781.37
-9.29%
688.34
1,218.63
-43.52%
EBIDTM
13.91%
21.59%
13.67%
19.86%
17.57%
18.37%
17.31%
27.18%
Other Income
230.68
74.04
211.56%
184.20
31.97
476.17%
144.92
45.34
219.63%
28.42
103.29
-72.49%
Interest
73.82
47.92
54.05%
68.72
43.90
56.54%
58.53
40.62
44.09%
54.00
48.44
11.48%
Depreciation
265.49
272.18
-2.46%
258.98
260.51
-0.59%
272.83
267.42
2.02%
280.35
230.91
21.41%
PBT
441.01
606.99
-27.34%
383.47
495.93
-22.68%
-942.04
518.67
-
382.41
1,042.57
-63.32%
Tax
172.91
154.06
12.24%
181.14
136.81
32.40%
-163.18
136.68
-
160.77
409.48
-60.74%
PAT
268.10
452.93
-40.81%
202.33
359.12
-43.66%
-778.86
381.99
-
221.64
633.09
-64.99%
PATM
6.79%
11.46%
5.25%
9.28%
-19.31%
8.98%
5.58%
14.12%
EPS
5.88
10.07
-41.61%
4.48
7.93
-43.51%
-17.33
8.42
-
4.91
14.02
-64.98%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
15,816.44
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
3,866.64
Net Sales Growth
-4.48%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
25.97%
 
Cost Of Goods Sold
5,592.25
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
1,604.09
Gross Profit
10,224.19
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
2,262.55
GP Margin
64.64%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
58.51%
Total Expenditure
13,342.74
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
3,127.36
Power & Fuel Cost
-
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
139.11
% Of Sales
-
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
3.60%
Employee Cost
-
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
474.16
% Of Sales
-
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
12.26%
Manufacturing Exp.
-
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
261.34
% Of Sales
-
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
6.76%
General & Admin Exp.
-
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
192.75
% Of Sales
-
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
4.98%
Selling & Distn. Exp.
-
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
354.48
% Of Sales
-
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
9.17%
Miscellaneous Exp.
-
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
121.51
354.48
% Of Sales
-
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
2.62%
EBITDA
2,473.70
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
739.28
EBITDA Margin
15.64%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
19.12%
Other Income
588.22
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
4.61
Interest
255.07
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
49.86
Depreciation
1,077.65
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
87.99
PBT
264.85
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Tax
351.64
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
98.30
Tax Rate
132.77%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
16.22%
PAT
-86.79
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
504.88
PAT before Minority Interest
-95.96
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
507.74
Minority Interest
-9.17
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
-2.86
PAT Margin
-0.55%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
13.06%
PAT Growth
-104.75%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
36.37%
 
Unadjusted EPS
-2.06
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84
60.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
1,424.82
Share Capital
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
82.82
Total Reserves
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
1,341.93
Non-Current Liabilities
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
1,339.71
Secured Loans
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
756.92
Unsecured Loans
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
466.35
Long Term Provisions
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
0.00
Current Liabilities
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
1,216.19
Trade Payables
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
710.25
Other Current Liabilities
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
323.23
Short Term Borrowings
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
0.00
Short Term Provisions
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
182.71
Total Liabilities
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97
Net Block
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
1,518.57
Gross Block
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
2,137.40
Accumulated Depreciation
2,459.58
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
618.83
Non Current Assets
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
1,764.10
Capital Work in Progress
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
222.62
Non Current Investment
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
21.56
Long Term Loans & Adv.
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
0.00
Other Non Current Assets
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
0.00
Current Assets
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
2,230.87
Current Investments
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
0.00
Inventories
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
957.16
Sundry Debtors
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
917.97
Cash & Bank
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
77.77
Other Current Assets
1,711.95
533.43
479.44
240.07
532.99
572.33
427.17
628.48
475.86
277.97
Short Term Loans & Adv.
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
277.97
Net Current Assets
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
1,014.68
Total Assets
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
3,994.97

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
469.54
PBT
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
606.04
Adjustment
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
144.21
Changes in Working Capital
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
-173.89
Cash after chg. in Working capital
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
576.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
-106.82
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,407.27
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
-509.62
Net Fixed Assets
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
-223.23
Net Investments
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
-181.38
Others
-1,564.03
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
-105.01
Cash from Financing Activity
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
-167.15
Net Cash Inflow / Outflow
-1,148.18
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
-207.23
Opening Cash & Equivalents
2,799.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
270.66
Closing Cash & Equivalent
1,651.29
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99
68.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
34.41
ROA
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
13.83%
ROE
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
37.55%
ROCE
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
25.57%
Fixed Asset Turnover
1.20
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
2.05
Receivable days
109.70
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
77.48
Inventory Days
84.35
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
81.42
Payable days
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
62.70
Cash Conversion Cycle
125.48
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
96.21
Total Debt/Equity
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
0.86
Interest Cover
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71
13.15

Annual Reports:

News Update:


  • Lupin developing new drugs to treat cancer, metabolic disorders
    14th Jan 2019, 09:34 AM

    The NDDD is focused and committed on developing a pipeline of highly differentiated and innovative new chemical entities

    Read More
  • Lupin recalls over 23,000 bottles of antibiotic drug in US
    9th Jan 2019, 14:48 PM

    The company is recalling the lot due to below specification results for assay

    Read More
  • Lupin gets nod from EC for Orphan Drug NaMuscla
    8th Jan 2019, 11:10 AM

    The company has partnering discussions ongoing for commercialization of NaMuscla in European territories outside Germany and the UK

    Read More
  • Lupin gets USFDA’s approval for Lurasidone Hydrochloride Tablets
    7th Jan 2019, 14:30 PM

    Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg had annual sales of approximately $3217.3 million in the US

    Read More
  • Lupin gets USFDA’s nod for Clobazam Oral Suspension
    31st Dec 2018, 16:08 PM

    Clobazam Oral Suspension, 2.5 mg/mL had annual sales of approximately $260.2 million in the US

    Read More
  • Lupin, AbbVie enters into partnership to develop and commercialize Novel Oncology Drug
    24th Dec 2018, 10:09 AM

    AbbVie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors

    Read More
  • Lupin gets USFDA’s nod for Clobazam Tablets
    17th Dec 2018, 14:38 PM

    Onfi Tablets, 10 mg and 20 mg had annual sales of approximately $601.2 million in the US

    Read More
  • Lupin gets USFDA’s tentative approval for Tadalafil Tablets
    17th Dec 2018, 14:05 PM

    Lupin's Tadalafil Tablets USP, 20 mg is the generic version of Lilly's Adcirca Tablets, 20 mg

    Read More
  • Lupin gets USFDA’s tentative approval for Dimethyl Fumarate Delayed Release Capsules
    13th Dec 2018, 16:11 PM

    Tecfidera Capsules, 120 mg and 240 mg had annual sales of approximately $3,545.4 million in the US

    Read More
  • Lupin receives tentative USFDA approval for Apixaban Tablets
    10th Dec 2018, 16:25 PM

    Lupin's Apixaban Tablets, 2.5 mg and 5mg is the generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg

    Read More
  • Lupin receives EIR from USFDA for Pithampur Unit-3
    10th Dec 2018, 14:06 PM

    The inspection at the site was conducted between June 12, 2017 and June 16, 2017

    Read More
  • USFDA completes inspection of Lupin's Mandideep location
    5th Dec 2018, 12:28 PM

    The inspection at Unit-2, the Cardiovascular ‘Pril’ API facilities closed with 4 observations

    Read More
  • Lupin launches generic Silodosin Capsules
    4th Dec 2018, 15:53 PM

    Rapaflo had annual sales of $198.5 million in the US

    Read More
  • Lupin launches generic Nystatin and Triamcinolone Acetonide Cream
    30th Nov 2018, 14:18 PM

    Nystatin and Triamcinolone Acetonide Cream had annual sales of $54.3 million in the US

    Read More
  • Lupin receives EIR from USFDA for Tarapur facility
    27th Nov 2018, 12:47 PM

    The inspection conducted between August 27 and August 31, 2018 concluded with one inspectional observation

    Read More
  • Lupin gets USFDA’s nod for Clomipramine Hydrochloride Capsules
    26th Nov 2018, 12:57 PM

    Anafranil Capsules, 25 mg, 50 mg, and 75 mg had annual sales of approximately $109.6 million in the US

    Read More
  • Lupin receives USFDA approval for Potassium Chloride for Oral Solution
    26th Nov 2018, 12:22 PM

    Potassium Chloride for Oral Solution USP, 20 mEq had annual sales of approximately $105 million in the US

    Read More
  • Lupin launches India's first chatbot for patients
    24th Nov 2018, 10:03 AM

    ANYA is an intelligent and patient-friendly chat bot trained to help patients with health-related concerns as part of their disease management

    Read More
  • Lupin launches generic Tetrabenazine Tablets
    21st Nov 2018, 11:11 AM

    It is indicated for the treatment of chorea associated with Huntington’s disease

    Read More
  • Lupin receives USFDA's approval for Decitabine for Injection
    15th Nov 2018, 11:24 AM

    Decitabine for Injection, 50 mg/vial, Single-Dose Vial had annual sales of approximately $135.9 million in the US

    Read More
  • Lupin receives USFDA approval for Budesonide Inhalation Suspension
    13th Nov 2018, 11:47 AM

    Budesonide Inhalation Suspension, 0.5 mg/2 mLSingle-DoseAmpules had annual sales of approximately $474.5 million in the US

    Read More
  • Lupin launches generic Atovaquone Oral Suspension USP in US
    12th Nov 2018, 16:00 PM

    It is indicated for the prevention of Pneumocystis jirovecii pneuomonia in adults and adolescents aged 13 years and older

    Read More
  • Lupin's Nagpur facility receives EIR from USFDA
    12th Nov 2018, 09:53 AM

    The inspection conducted in September 2018 concluded without any observations

    Read More
  • Lupin’s US arm recalls 6,752 bottles of Testosterone Topical solution from US
    6th Nov 2018, 16:17 PM

    The reason for recall is Defective Container Repetitive complaints received indicating pump not working

    Read More
  • Lupin receives FDA approval for Doxercalciferol Injection
    5th Nov 2018, 16:28 PM

    Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vial is the generic version of Genzyme's Hectorol Injection

    Read More
  • Lupin reports 42% fall in Q2 consolidated net profit
    2nd Nov 2018, 11:46 AM

    Total income of the company increased by 3.87% at Rs 4,181.74 crore for Q2FY19

    Read More
  • Lupin - Quarterly Results
    31st Oct 2018, 14:43 PM

    Read More
  • Lupin receives USFDA’s approval for generic Triamcinolone Acetonide Ointment
    22nd Oct 2018, 16:19 PM

    It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

    Read More
  • Lupin Neurosciences receives positive CHMP opinion for NaMuscla
    20th Oct 2018, 09:25 AM

    It is for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders

    Read More
  • USFDA completes inspection at Lupin’s Indore facility
    19th Oct 2018, 16:00 PM

    The inspection was a GMP inspection for the facility and also a Pre-Approval Inspection (PAI) for the company's Tiotropium DPI ANDA

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.